Braxia Scientific Corp. announced it has successfully launched KetaMD in Florida. KetaMD on boarded new patients and completed initial ketamine treatments.

Eligible patients, as determined by one of KetaMD's licensed Florida healthcare practitioners, received medically supervised treatments, guided virtually by registered nurses with mental health expertise, while in the comfort of their home. KetaMD Inc. ("KetaMD"), a wholly owned subsidiary of Braxia Scientific, is an innovative end-to-end telemedicine platform, that provides access to safe, affordable, reliable and potentially life-changing at-home ketamine treatments for people suffering from mental health disorders such as depression, bipolar disorder, anxiety and post-traumatic stress disorder (PTSD). In multiple studies, ketamine has also been shown to have rapid and persistent benefits for acute care in suicidal patients who often suffer from mental health challenges.

As National Suicide Awareness month kicks off, KetaMD has ramped up operations and session availability to provide additional support to Florida residents in need of treatment.